TLDR
- ARK sold 19,491 shares of Advanced Micro Devices worth nearly $9.9 million through its ARKK ETF
- ARK bought 575,700 shares of Archer Aviation for $3.4 million, signaling interest in urban air mobility
- Cerebras Systems saw ARK buy 93,290 shares worth $17.2 million despite the stock falling 32.4% since May
- Cerebras reported 103% year-over-year revenue growth to $209.9 million in Q2, with cloud revenue up 287%
- ARK also sold Palantir Technologies shares worth $6.5 million while adding to Beam Therapeutics and CRISPR Therapeutics
Cathie Wood’s ARK Invest made a string of trades on September 9, 2026, selling out of some well-known tech names while doubling down on AI infrastructure and biotech.
The biggest sale was Advanced Micro Devices. ARK offloaded 19,491 shares through its ARKK ETF, totaling nearly $9.9 million. This continues a pattern of ARK reducing its AMD position over the past week.
Advanced Micro Devices, Inc., AMD
ARK also sold 38,395 shares of Palantir Technologies for $6.5 million and trimmed its Tempus AI position by selling 68,759 shares worth $4.4 million.
On the buy side, ARK purchased 575,700 shares of Archer Aviation for $3.4 million. Archer develops electric air taxis, and this purchase adds to ARK’s bet on the urban air mobility space.
ARK’s Big Bet on Cerebras
The more closely watched move is ARK’s continued buying of Cerebras Systems. On August 25, ARK bought 93,290 shares across two ETFs, with the position worth around $17.2 million at the time.
Cerebras stock has been under pressure. It dropped 8% in the past month and is down 32.4% since its May 14 debut. The selloff followed its August 18 Supernova event, when investors locked in profits.
Despite this, Wood appears to see long-term value. Cerebras reported Q2 revenue of $209.9 million, a 103% jump from a year ago. Cloud revenue alone hit $127.7 million, up 287% year-over-year.
Margins have been a concern. Core gross margin came in at 40.6% in Q2, down from 46.5% in Q1. Management says the pressure is temporary, caused by renting back systems from cloud customers at higher costs.
The company expects margins to improve by Q4 as it brings more owned systems online. Long-term, management is targeting a core gross margin above 60%.
Cerebras Balance Sheet and Analyst Views
Cerebras ended Q2 with over $8.6 billion in cash, restricted cash, and marketable securities. It also has an unused $850 million revolving credit facility.
The company has secured over 600 megawatts of data center capacity, either live or scheduled for delivery by end of 2027. Manufacturing capacity is now four times larger than in the first half of 2025.
Cerebras currently makes up 2.68% of the ARK Innovation ETF and 2.73% of the ARK Next Generation Internet ETF.
On Wall Street, 8 of 11 analysts rate Cerebras a Strong Buy. The average price target of $283.91 points to potential upside of 35.1%, while the high target of $330 implies gains of 57.1% over 12 months.
ARK also bought shares of Beam Therapeutics, CRISPR Therapeutics, and Robinhood Markets during the same trading session, while selling Twist Bioscience and 10X Genomics.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.